Almac expands clinical trial supply distribution network

Published: 29-Jun-2011 Featured companies: Almac Group
Regulatory Logistics

Five new depots added in the Asia Pacific region


Almac’s Clinical Services business unit, a leading provider of contract services to the clinical trial supply industry, has increased its presence in the Asia Pacific region by adding five new depots located in Japan, Thailand, Hong Kong and Taiwan to its extensive global depot network.

These latest developments in the Asian market enable Almac to provide customers with even more flexibility in their supply chain solution for their specific country clinical trial requirements. The number of depots within the network is now 36 with a further five planned for 2012.

Almac’s Global Depot Network is managed by dedicated depot management teams who serve as the central contact point for the network and also perform regular visits to the depots which are fully audited and GMP compliant. In line with continuous depot expansion the resources within the Depot Management Team have also increased over the past six months. There are now 15 members of staff who are located in the UK, US and Brazil and are dedicated to managing protocols across the depot network.

‘The latest depots are a very welcome addition to our network and have been strategically positioned in locations worldwide to ensure we can supply emerging markets with a consistent high level of service,’ said Mark Woolf, global depot manager for Almac’s Clinical Services business unit.

Featured companies

See more

You may also like

Manufacturing

Almac completes “outstanding” grade by the KTP

Read more
The Innovate UK-funded KTP aimed to embed flow technologies to ensure long term security of supply for key raw materials through development

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  3. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  4. The rising importance of preservative efficacy testing When considering the regulation and validation of pharmaceutical products, the efficacy of the active pharmaceutical ingredient (API) is often the main concern
  5. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey

Relevant companies

See more

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Almac completes “outstanding” grade by the KTP

The Innovate UK-funded KTP aimed to embed flow technologies to ensure long term security of supply for key raw materials through development
Manufacturing

Almac Sciences Ireland secures HPRA certification

This additional certification enables Almac to perform biologics testing for the determination of product quality attributes
Regulatory

Almac receives product approval by MHRA and Health Canada

The company’s site provides a range of solutions for blister packs, stickpacks, and kitting
Packaging

Enhancing clinical trial supply with JTM: part I

In a constantly changing world, the pharmaceutical industry is having to adopt its practices to serve the needs of a rapidly growing and ageing population and develop innovative personalised medicines. Almac has responded to these demands with a Just-in-Time Manufacturing solution that fulfils the requirements of a high value, time sensitive clinical supply chain. Dr Kevin Robinson spoke to Natalie Balanovsky, Just-in-Time Manufacturing Solutions Manager, and Mark Rohlfing, Vice President of Operations, to find out more
Regulatory

Almac welcomes confirmation that Northern Ireland will remain aligned with the EU post-Brexit

Move offers Almac clients unique, unfettered and flexible access to both the UK and European markets
Regulatory

Almac Group supports two COVID-19 clinical studies in sub-Saharan Africa

Grant awarded from the COVID-19 Therapeutics Accelerator, an Initiative by the Bill & Melinda Gates Foundation, Wellcome and Mastercard
Manufacturing

Almac Group increases volume of clinical essential supplies to patients at home

Direct to Patient via Site and “Almac to Patient” Services are part of Almac Clinical Services’ ongoing response to COVID-19
Subscribe now